TP53 and cancer: Our recent findings strongly indicate that depletion of RUNX2 improves the anti-cancer drug sensitivity of p53-proficient osteosarcoma U2OS cells as well as p53-deficient pancreatic cancer AsPC-1 cells in a p53 family-dependent manner.37, 38, 39 As described,25 mutant p53 exhibits a strong dominant-negative behavior against wild-type p53, TAp73 and TAp63, raising a question whether knockdown of RUNX2 could also enhance the anti-cancer drug sensitivity of cancerous cells bearing p53 mutation.